Relevant conflicts of interest/financial disclosures: This study was supported by the Parkinson's Disease Foundation, New York, New York. Drs. Goldman and Goetz have received research support from the Parkinson's Disease Foundation. Dr. Berry-Kravis has consulted and had clinical trial funding from Novartis, Roche, Seaside Therapeutics and Neuropharm LTD for projects unrelated to Parkinson's Disease or hallucinations. Full financial disclosures and author roles may be found in the online version of this article.
Letters: New Observation
Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations†
Version of Record online: 19 APR 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 9, pages 1781–1783, 1 August 2011
How to Cite
Goldman, J. G., Marr, D., Zhou, L., Ouyang, B., Leurgans, S. E., Berry-Kravis, E. and Goetz, C. G. (2011), Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov. Disord., 26: 1781–1783. doi: 10.1002/mds.23655
- Issue online: 9 AUG 2011
- Version of Record online: 19 APR 2011
- Manuscript Accepted: 3 JAN 2011
- Manuscript Revised: 29 DEC 2010
- Manuscript Received: 19 NOV 2010
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.